Efficacy of monoclonal antibody, insulin, erythropoietin and granulocyte colony-stimulating factor, etc. were all very ideal, as viewed from results of phase III clinical research of various biosimilars in 2014. Manufacturers of original drugs continued to try every means to protect their vested interest when the R&D driving force became increasingly larger: Johnson & Johnson and Amgen separately accused Sandoz and Celltrion in the U.S. courts in 2014-and won. Some analysts considered previously that the launch of biosimilars in the U.S. market might be extended a few years due to the extension of court judgments and patent term, however, viewed from the case of Novartis Zarzio, the launch time of the first biosimilar in the U.S. may be advanced.
Cooperation among R&D and production enterprises for biosimilars has been reduced in the last several years. But there were still 15 acquisition and cooperation events in 2014, many of which happened in the emerging markets.
Viewed from the current global layout, apart from Russia, China, Central Asia and Africa, etc. the rest of the regions have opened the approval of biosimilars. There had been totally 280 biosimilars under clinical trial by the end of 2014, with the annual growth rate being 20%, wherein, there were totally 57 in Europe, the U.S. and India.
